Brauner R, Rappaport R, Prevot C, Czernichow P, Zucker J M, Bataini P, Lemerle J, Sarrazin D, Guyda H J
Pediatric Endocrinology Unit, Hôpital des Enfants-Malades, Paris, France.
J Clin Endocrinol Metab. 1989 Feb;68(2):346-51. doi: 10.1210/jcem-68-2-346.
Although GH deficiency (GHD) is the most frequent hormonal abnormality that occurs after cranial radiation, the natural course of this complication and its relationship to growth in children are not known. Therefore, we undertook a 2-yr prospective study of 16 children, aged 1.7-15 yr at the time of treatment, who received cranial [31-42 Gy (1 Gy = 100 rads)] and spinal radiation for medulloblastoma or ependymoma (group I). Their growth was compared to that of 11 children given similar doses of cranial radiation only (group II). The mean plasma GH response to arginine-insulin test (AITT) was 9.1 +/- 1.5 (+/- SE) micrograms/L in group I and 8.5 +/- 1.8 micrograms/L in group II (P = NS). After 2 yr, 16 of the 27 children had a peak plasma GH value below 8 micrograms/L after AITT, and 10 children had a peak response less than 5 micrograms/L. In addition, in group I, AITT and sleep-related GH secretion were compared; at the 2 yr follow-up only 3 of 13 children had discrepant results. At the 2 yr follow-up children treated by cranial and spinal radiation had a mean height of -1.46 +/- 0.40 SD below the normal mean. In contrast, the children given only cranial radiation had a mean height of -0.15 +/- 0.18 SD; P less than 0.02. Therefore, most of the growth retardation appeared to be due to lack of spinal growth. GHD is thus an early complication of cranial radiation in these children, and no significant growth retardation can be attributed to GHD during the first 2 yr. These data contribute to the organization of follow-up in irradiated children in order to decide when human GH treatment is necessary.
尽管生长激素缺乏症(GHD)是颅脑放疗后最常见的激素异常情况,但这种并发症的自然病程及其与儿童生长的关系尚不清楚。因此,我们对16名儿童进行了一项为期2年的前瞻性研究,这些儿童在治疗时年龄为1.7至15岁,因髓母细胞瘤或室管膜瘤接受了颅脑[31 - 42 Gy(1 Gy = 100 rads)]和脊髓放疗(第一组)。将他们的生长情况与11名仅接受相同剂量颅脑放疗的儿童(第二组)进行比较。第一组对精氨酸 - 胰岛素试验(AITT)的平均血浆生长激素反应为9.1±1.5(±SE)μg/L,第二组为8.5±1.8μg/L(P = 无显著差异)。2年后,27名儿童中有16名在AITT后血浆生长激素峰值低于8μg/L,10名儿童的峰值反应低于5μg/L。此外,在第一组中,对AITT和与睡眠相关的生长激素分泌进行了比较;在2年随访时,13名儿童中只有3名结果不一致。在2年随访时,接受颅脑和脊髓放疗的儿童平均身高比正常均值低1.46±0.40标准差。相比之下,仅接受颅脑放疗的儿童平均身高比正常均值低0.15±0.18标准差;P<0.02。因此,大多数生长迟缓似乎是由于脊柱生长不足所致。GHD是这些儿童颅脑放疗的早期并发症,在最初2年内没有明显的生长迟缓可归因于GHD。这些数据有助于为接受放疗的儿童组织随访,以便决定何时需要进行人生长激素治疗。